nodes	percent_of_prediction	percent_of_DWPC	metapath
Vigabatrin—L-Glutamine—TGM2—esophageal cancer	0.0403	1	CrCbGaD
Vigabatrin—Wound secretion—Capecitabine—esophageal cancer	0.0357	0.0447	CcSEcCtD
Vigabatrin—Mental retardation—Capecitabine—esophageal cancer	0.0237	0.0297	CcSEcCtD
Vigabatrin—Neurotoxicity—Cisplatin—esophageal cancer	0.0181	0.0227	CcSEcCtD
Vigabatrin—Sensory disturbance—Capecitabine—esophageal cancer	0.0167	0.0209	CcSEcCtD
Vigabatrin—Developmental delay—Capecitabine—esophageal cancer	0.0136	0.017	CcSEcCtD
Vigabatrin—Congenital anomaly—Capecitabine—esophageal cancer	0.0136	0.017	CcSEcCtD
Vigabatrin—GABBR1—Activation of G protein gated Potassium channels—GNG7—esophageal cancer	0.0136	0.101	CbGpPWpGaD
Vigabatrin—Neurotoxicity—Capecitabine—esophageal cancer	0.0134	0.0167	CcSEcCtD
Vigabatrin—Depressed mood—Capecitabine—esophageal cancer	0.0116	0.0145	CcSEcCtD
Vigabatrin—GABBR1—Inwardly rectifying K+ channels—GNG7—esophageal cancer	0.0114	0.0851	CbGpPWpGaD
Vigabatrin—Optic neuritis—Cisplatin—esophageal cancer	0.0114	0.0143	CcSEcCtD
Vigabatrin—Retinal disorder—Methotrexate—esophageal cancer	0.0108	0.0135	CcSEcCtD
Vigabatrin—Neurotoxicity—Methotrexate—esophageal cancer	0.00995	0.0124	CcSEcCtD
Vigabatrin—GABBR1—Activation of GABAB receptors—GNG7—esophageal cancer	0.00972	0.0723	CbGpPWpGaD
Vigabatrin—Myoclonus—Capecitabine—esophageal cancer	0.00862	0.0108	CcSEcCtD
Vigabatrin—Infection—Carboplatin—esophageal cancer	0.0085	0.0106	CcSEcCtD
Vigabatrin—Encephalopathy—Capecitabine—esophageal cancer	0.00807	0.0101	CcSEcCtD
Vigabatrin—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00768	0.0096	CcSEcCtD
Vigabatrin—Laryngeal pain—Capecitabine—esophageal cancer	0.0076	0.00951	CcSEcCtD
Vigabatrin—GABBR1—GABA receptor activation—GNG7—esophageal cancer	0.00745	0.0554	CbGpPWpGaD
Vigabatrin—Dysarthria—Cisplatin—esophageal cancer	0.00743	0.0093	CcSEcCtD
Vigabatrin—Pain—Carboplatin—esophageal cancer	0.00731	0.00915	CcSEcCtD
Vigabatrin—Body temperature increased—Carboplatin—esophageal cancer	0.00676	0.00845	CcSEcCtD
Vigabatrin—Otitis media—Capecitabine—esophageal cancer	0.00666	0.00832	CcSEcCtD
Vigabatrin—Memory impairment—Capecitabine—esophageal cancer	0.0066	0.00826	CcSEcCtD
Vigabatrin—Encephalopathy—Methotrexate—esophageal cancer	0.00601	0.00752	CcSEcCtD
Vigabatrin—Contusion—Capecitabine—esophageal cancer	0.00594	0.00743	CcSEcCtD
Vigabatrin—GABBR1—bronchus—esophageal cancer	0.00582	0.228	CbGeAlD
Vigabatrin—Deafness—Cisplatin—esophageal cancer	0.00571	0.00713	CcSEcCtD
Vigabatrin—Nasal congestion—Cisplatin—esophageal cancer	0.0056	0.00701	CcSEcCtD
Vigabatrin—Dysarthria—Capecitabine—esophageal cancer	0.00548	0.00685	CcSEcCtD
Vigabatrin—Amnesia—Cisplatin—esophageal cancer	0.00543	0.00679	CcSEcCtD
Vigabatrin—Gait disturbance—Capecitabine—esophageal cancer	0.00531	0.00664	CcSEcCtD
Vigabatrin—Coordination abnormal—Capecitabine—esophageal cancer	0.00528	0.0066	CcSEcCtD
Vigabatrin—Pulmonary embolism—Capecitabine—esophageal cancer	0.00518	0.00648	CcSEcCtD
Vigabatrin—Stupor—Methotrexate—esophageal cancer	0.00517	0.00646	CcSEcCtD
Vigabatrin—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.0051	0.00638	CcSEcCtD
Vigabatrin—Depressed level of consciousness—Capecitabine—esophageal cancer	0.005	0.00626	CcSEcCtD
Vigabatrin—Candida infection—Capecitabine—esophageal cancer	0.00495	0.00619	CcSEcCtD
Vigabatrin—Face oedema—Cisplatin—esophageal cancer	0.00493	0.00616	CcSEcCtD
Vigabatrin—Irritability—Cisplatin—esophageal cancer	0.00487	0.00609	CcSEcCtD
Vigabatrin—Oesophagitis—Capecitabine—esophageal cancer	0.00474	0.00592	CcSEcCtD
Vigabatrin—Breast disorder—Cisplatin—esophageal cancer	0.00461	0.00577	CcSEcCtD
Vigabatrin—Nasopharyngitis—Cisplatin—esophageal cancer	0.00456	0.00571	CcSEcCtD
Vigabatrin—Abnormal vision—Capecitabine—esophageal cancer	0.00452	0.00565	CcSEcCtD
Vigabatrin—GABBR1—Potassium Channels—GNG7—esophageal cancer	0.00452	0.0336	CbGpPWpGaD
Vigabatrin—Mental disability—Capecitabine—esophageal cancer	0.0045	0.00562	CcSEcCtD
Vigabatrin—Speech disorder—Methotrexate—esophageal cancer	0.00449	0.00561	CcSEcCtD
Vigabatrin—Ear pain—Capecitabine—esophageal cancer	0.00441	0.00551	CcSEcCtD
Vigabatrin—Abdominal discomfort—Cisplatin—esophageal cancer	0.00423	0.00529	CcSEcCtD
Vigabatrin—Vascular purpura—Capecitabine—esophageal cancer	0.00421	0.00526	CcSEcCtD
Vigabatrin—Deafness—Capecitabine—esophageal cancer	0.00421	0.00526	CcSEcCtD
Vigabatrin—Eye pain—Capecitabine—esophageal cancer	0.00417	0.00521	CcSEcCtD
Vigabatrin—Dysarthria—Methotrexate—esophageal cancer	0.00408	0.0051	CcSEcCtD
Vigabatrin—Amnesia—Capecitabine—esophageal cancer	0.004	0.00501	CcSEcCtD
Vigabatrin—Increased appetite—Capecitabine—esophageal cancer	0.004	0.00501	CcSEcCtD
Vigabatrin—Thirst—Capecitabine—esophageal cancer	0.00395	0.00494	CcSEcCtD
Vigabatrin—Respiratory failure—Methotrexate—esophageal cancer	0.00393	0.00491	CcSEcCtD
Vigabatrin—Purpura—Capecitabine—esophageal cancer	0.0039	0.00488	CcSEcCtD
Vigabatrin—Pulmonary embolism—Methotrexate—esophageal cancer	0.00386	0.00482	CcSEcCtD
Vigabatrin—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00386	0.00482	CcSEcCtD
Vigabatrin—Lethargy—Capecitabine—esophageal cancer	0.00384	0.0048	CcSEcCtD
Vigabatrin—Conjunctivitis—Cisplatin—esophageal cancer	0.00382	0.00478	CcSEcCtD
Vigabatrin—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00376	0.0047	CcSEcCtD
Vigabatrin—Diplopia—Capecitabine—esophageal cancer	0.00376	0.0047	CcSEcCtD
Vigabatrin—Osteoarthritis—Capecitabine—esophageal cancer	0.00376	0.0047	CcSEcCtD
Vigabatrin—Pain in extremity—Capecitabine—esophageal cancer	0.00376	0.0047	CcSEcCtD
Vigabatrin—GABBR1—lung—esophageal cancer	0.00376	0.147	CbGeAlD
Vigabatrin—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00373	0.00466	CcSEcCtD
Vigabatrin—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00372	0.00465	CcSEcCtD
Vigabatrin—Face oedema—Capecitabine—esophageal cancer	0.00363	0.00454	CcSEcCtD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00363	0.027	CbGpPWpGaD
Vigabatrin—Irritability—Capecitabine—esophageal cancer	0.00359	0.00449	CcSEcCtD
Vigabatrin—Mood swings—Capecitabine—esophageal cancer	0.00356	0.00446	CcSEcCtD
Vigabatrin—Ataxia—Capecitabine—esophageal cancer	0.00354	0.00442	CcSEcCtD
Vigabatrin—SLC36A1—digestive system—esophageal cancer	0.00353	0.138	CbGeAlD
Vigabatrin—Connective tissue disorder—Cisplatin—esophageal cancer	0.00347	0.00434	CcSEcCtD
Vigabatrin—Abdominal pain upper—Capecitabine—esophageal cancer	0.00344	0.0043	CcSEcCtD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00343	0.0255	CbGpPWpGaD
Vigabatrin—Visual impairment—Cisplatin—esophageal cancer	0.0034	0.00425	CcSEcCtD
Vigabatrin—Breast disorder—Capecitabine—esophageal cancer	0.0034	0.00425	CcSEcCtD
Vigabatrin—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00339	0.00424	CcSEcCtD
Vigabatrin—Nasopharyngitis—Capecitabine—esophageal cancer	0.00336	0.00421	CcSEcCtD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00332	0.0247	CbGpPWpGaD
Vigabatrin—Eye disorder—Cisplatin—esophageal cancer	0.0033	0.00413	CcSEcCtD
Vigabatrin—Tinnitus—Cisplatin—esophageal cancer	0.00329	0.00412	CcSEcCtD
Vigabatrin—Abdominal distension—Capecitabine—esophageal cancer	0.00327	0.00409	CcSEcCtD
Vigabatrin—Influenza—Capecitabine—esophageal cancer	0.00325	0.00407	CcSEcCtD
Vigabatrin—Bronchitis—Capecitabine—esophageal cancer	0.00313	0.00391	CcSEcCtD
Vigabatrin—Abdominal discomfort—Capecitabine—esophageal cancer	0.00312	0.0039	CcSEcCtD
Vigabatrin—Malnutrition—Cisplatin—esophageal cancer	0.00307	0.00384	CcSEcCtD
Vigabatrin—ABAT—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00303	0.0225	CbGpPWpGaD
Vigabatrin—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00302	0.00378	CcSEcCtD
Vigabatrin—Weight increased—Capecitabine—esophageal cancer	0.00296	0.0037	CcSEcCtD
Vigabatrin—Muscle spasms—Cisplatin—esophageal cancer	0.00296	0.0037	CcSEcCtD
Vigabatrin—SLC36A1—lung—esophageal cancer	0.00295	0.115	CbGeAlD
Vigabatrin—ABAT—lung—esophageal cancer	0.00293	0.115	CbGeAlD
Vigabatrin—Pneumonia—Capecitabine—esophageal cancer	0.00292	0.00365	CcSEcCtD
Vigabatrin—Infestation NOS—Capecitabine—esophageal cancer	0.0029	0.00363	CcSEcCtD
Vigabatrin—Infestation—Capecitabine—esophageal cancer	0.0029	0.00363	CcSEcCtD
Vigabatrin—Vision blurred—Cisplatin—esophageal cancer	0.0029	0.00362	CcSEcCtD
Vigabatrin—Depression—Capecitabine—esophageal cancer	0.00289	0.00362	CcSEcCtD
Vigabatrin—Tremor—Cisplatin—esophageal cancer	0.00288	0.0036	CcSEcCtD
Vigabatrin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00287	0.00359	CcSEcCtD
Vigabatrin—Lethargy—Methotrexate—esophageal cancer	0.00286	0.00357	CcSEcCtD
Vigabatrin—Ill-defined disorder—Cisplatin—esophageal cancer	0.00285	0.00357	CcSEcCtD
Vigabatrin—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00284	0.00355	CcSEcCtD
Vigabatrin—Anaemia—Cisplatin—esophageal cancer	0.00284	0.00355	CcSEcCtD
Vigabatrin—ABAT—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00284	0.0211	CbGpPWpGaD
Vigabatrin—Conjunctivitis—Capecitabine—esophageal cancer	0.00282	0.00352	CcSEcCtD
Vigabatrin—Urinary tract infection—Capecitabine—esophageal cancer	0.00282	0.00352	CcSEcCtD
Vigabatrin—Osteoarthritis—Methotrexate—esophageal cancer	0.0028	0.0035	CcSEcCtD
Vigabatrin—Malaise—Cisplatin—esophageal cancer	0.00277	0.00347	CcSEcCtD
Vigabatrin—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00274	0.00343	CcSEcCtD
Vigabatrin—Irritability—Methotrexate—esophageal cancer	0.00267	0.00334	CcSEcCtD
Vigabatrin—Convulsion—Cisplatin—esophageal cancer	0.00266	0.00333	CcSEcCtD
Vigabatrin—Mood swings—Methotrexate—esophageal cancer	0.00265	0.00332	CcSEcCtD
Vigabatrin—Ataxia—Methotrexate—esophageal cancer	0.00263	0.00329	CcSEcCtD
Vigabatrin—Myalgia—Cisplatin—esophageal cancer	0.00262	0.00327	CcSEcCtD
Vigabatrin—Anxiety—Cisplatin—esophageal cancer	0.00261	0.00326	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0026	0.00325	CcSEcCtD
Vigabatrin—Hypoaesthesia—Capecitabine—esophageal cancer	0.00259	0.00324	CcSEcCtD
Vigabatrin—Discomfort—Cisplatin—esophageal cancer	0.00259	0.00323	CcSEcCtD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00257	0.0192	CbGpPWpGaD
Vigabatrin—GABBR1—lymph node—esophageal cancer	0.00257	0.1	CbGeAlD
Vigabatrin—Oedema peripheral—Capecitabine—esophageal cancer	0.00256	0.00321	CcSEcCtD
Vigabatrin—Connective tissue disorder—Capecitabine—esophageal cancer	0.00256	0.0032	CcSEcCtD
Vigabatrin—Breast disorder—Methotrexate—esophageal cancer	0.00253	0.00316	CcSEcCtD
Vigabatrin—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00252	0.00315	CcSEcCtD
Vigabatrin—Oedema—Cisplatin—esophageal cancer	0.00251	0.00314	CcSEcCtD
Vigabatrin—Visual impairment—Capecitabine—esophageal cancer	0.00251	0.00314	CcSEcCtD
Vigabatrin—Infection—Cisplatin—esophageal cancer	0.00249	0.00312	CcSEcCtD
Vigabatrin—Erythema multiforme—Capecitabine—esophageal cancer	0.00246	0.00308	CcSEcCtD
Vigabatrin—Nervous system disorder—Cisplatin—esophageal cancer	0.00246	0.00308	CcSEcCtD
Vigabatrin—GABBR1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00244	0.0182	CbGpPWpGaD
Vigabatrin—Skin disorder—Cisplatin—esophageal cancer	0.00244	0.00305	CcSEcCtD
Vigabatrin—Eye disorder—Capecitabine—esophageal cancer	0.00243	0.00304	CcSEcCtD
Vigabatrin—Tinnitus—Capecitabine—esophageal cancer	0.00243	0.00303	CcSEcCtD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00241	0.018	CbGpPWpGaD
Vigabatrin—Abdominal discomfort—Methotrexate—esophageal cancer	0.00232	0.0029	CcSEcCtD
Vigabatrin—ABAT—Neuronal System—GNG7—esophageal cancer	0.00232	0.0173	CbGpPWpGaD
Vigabatrin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00229	0.00286	CcSEcCtD
Vigabatrin—Mental disorder—Capecitabine—esophageal cancer	0.00228	0.00285	CcSEcCtD
Vigabatrin—Malnutrition—Capecitabine—esophageal cancer	0.00227	0.00283	CcSEcCtD
Vigabatrin—GABBR1—G alpha (i) signalling events—GNG7—esophageal cancer	0.00226	0.0168	CbGpPWpGaD
Vigabatrin—Paraesthesia—Cisplatin—esophageal cancer	0.00225	0.00282	CcSEcCtD
Vigabatrin—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00225	0.00281	CcSEcCtD
Vigabatrin—Erectile dysfunction—Methotrexate—esophageal cancer	0.00223	0.00279	CcSEcCtD
Vigabatrin—Back pain—Capecitabine—esophageal cancer	0.00219	0.00274	CcSEcCtD
Vigabatrin—Decreased appetite—Cisplatin—esophageal cancer	0.00218	0.00273	CcSEcCtD
Vigabatrin—Muscle spasms—Capecitabine—esophageal cancer	0.00218	0.00272	CcSEcCtD
Vigabatrin—ABAT—Neuronal System—ALDH2—esophageal cancer	0.00217	0.0162	CbGpPWpGaD
Vigabatrin—Pneumonia—Methotrexate—esophageal cancer	0.00217	0.00271	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00217	0.00271	CcSEcCtD
Vigabatrin—Drowsiness—Methotrexate—esophageal cancer	0.00216	0.0027	CcSEcCtD
Vigabatrin—Infestation NOS—Methotrexate—esophageal cancer	0.00216	0.0027	CcSEcCtD
Vigabatrin—Infestation—Methotrexate—esophageal cancer	0.00216	0.0027	CcSEcCtD
Vigabatrin—Depression—Methotrexate—esophageal cancer	0.00215	0.00269	CcSEcCtD
Vigabatrin—Pain—Cisplatin—esophageal cancer	0.00215	0.00268	CcSEcCtD
Vigabatrin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00214	0.00268	CcSEcCtD
Vigabatrin—Vision blurred—Capecitabine—esophageal cancer	0.00214	0.00267	CcSEcCtD
Vigabatrin—Tremor—Capecitabine—esophageal cancer	0.00212	0.00265	CcSEcCtD
Vigabatrin—Ill-defined disorder—Capecitabine—esophageal cancer	0.0021	0.00263	CcSEcCtD
Vigabatrin—Conjunctivitis—Methotrexate—esophageal cancer	0.0021	0.00262	CcSEcCtD
Vigabatrin—Anaemia—Capecitabine—esophageal cancer	0.00209	0.00262	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00207	0.0154	CbGpPWpGaD
Vigabatrin—Feeling abnormal—Cisplatin—esophageal cancer	0.00207	0.00258	CcSEcCtD
Vigabatrin—Malaise—Capecitabine—esophageal cancer	0.00204	0.00255	CcSEcCtD
Vigabatrin—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00204	0.00255	CcSEcCtD
Vigabatrin—Vertigo—Capecitabine—esophageal cancer	0.00204	0.00255	CcSEcCtD
Vigabatrin—SLC36A1—lymph node—esophageal cancer	0.00202	0.0789	CbGeAlD
Vigabatrin—ABAT—lymph node—esophageal cancer	0.00201	0.0784	CbGeAlD
Vigabatrin—GABBR1—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00199	0.0148	CbGpPWpGaD
Vigabatrin—Body temperature increased—Cisplatin—esophageal cancer	0.00198	0.00248	CcSEcCtD
Vigabatrin—Cough—Capecitabine—esophageal cancer	0.00198	0.00247	CcSEcCtD
Vigabatrin—GABBR1—Neuronal System—GNG7—esophageal cancer	0.00197	0.0147	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00195	0.0145	CbGpPWpGaD
Vigabatrin—Myalgia—Capecitabine—esophageal cancer	0.00193	0.00241	CcSEcCtD
Vigabatrin—Arthralgia—Capecitabine—esophageal cancer	0.00193	0.00241	CcSEcCtD
Vigabatrin—Chest pain—Capecitabine—esophageal cancer	0.00193	0.00241	CcSEcCtD
Vigabatrin—Anxiety—Capecitabine—esophageal cancer	0.00192	0.0024	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00192	0.0024	CcSEcCtD
Vigabatrin—Discomfort—Capecitabine—esophageal cancer	0.00191	0.00238	CcSEcCtD
Vigabatrin—Visual impairment—Methotrexate—esophageal cancer	0.00187	0.00233	CcSEcCtD
Vigabatrin—Confusional state—Capecitabine—esophageal cancer	0.00186	0.00233	CcSEcCtD
Vigabatrin—GABBR1—G alpha (i) signalling events—ANXA1—esophageal cancer	0.00185	0.0138	CbGpPWpGaD
Vigabatrin—Oedema—Capecitabine—esophageal cancer	0.00185	0.00231	CcSEcCtD
Vigabatrin—GABBR1—Neuronal System—ALDH2—esophageal cancer	0.00185	0.0138	CbGpPWpGaD
Vigabatrin—Hypersensitivity—Cisplatin—esophageal cancer	0.00185	0.00231	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00184	0.0137	CbGpPWpGaD
Vigabatrin—Infection—Capecitabine—esophageal cancer	0.00184	0.0023	CcSEcCtD
Vigabatrin—Erythema multiforme—Methotrexate—esophageal cancer	0.00183	0.00229	CcSEcCtD
Vigabatrin—Nervous system disorder—Capecitabine—esophageal cancer	0.00181	0.00227	CcSEcCtD
Vigabatrin—Eye disorder—Methotrexate—esophageal cancer	0.00181	0.00226	CcSEcCtD
Vigabatrin—Tinnitus—Methotrexate—esophageal cancer	0.00181	0.00226	CcSEcCtD
Vigabatrin—GABBR1—G alpha (i) signalling events—SST—esophageal cancer	0.0018	0.0134	CbGpPWpGaD
Vigabatrin—Asthenia—Cisplatin—esophageal cancer	0.0018	0.00225	CcSEcCtD
Vigabatrin—Skin disorder—Capecitabine—esophageal cancer	0.0018	0.00225	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00176	0.0131	CbGpPWpGaD
Vigabatrin—Diarrhoea—Cisplatin—esophageal cancer	0.00172	0.00215	CcSEcCtD
Vigabatrin—Mental disorder—Methotrexate—esophageal cancer	0.0017	0.00212	CcSEcCtD
Vigabatrin—Malnutrition—Methotrexate—esophageal cancer	0.00169	0.00211	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00169	0.0125	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00169	0.0125	CbGpPWpGaD
Vigabatrin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00168	0.00211	CcSEcCtD
Vigabatrin—Insomnia—Capecitabine—esophageal cancer	0.00167	0.00209	CcSEcCtD
Vigabatrin—Paraesthesia—Capecitabine—esophageal cancer	0.00166	0.00208	CcSEcCtD
Vigabatrin—Back pain—Methotrexate—esophageal cancer	0.00163	0.00204	CcSEcCtD
Vigabatrin—Dyspepsia—Capecitabine—esophageal cancer	0.00163	0.00204	CcSEcCtD
Vigabatrin—Decreased appetite—Capecitabine—esophageal cancer	0.00161	0.00201	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.0016	0.002	CcSEcCtD
Vigabatrin—Vomiting—Cisplatin—esophageal cancer	0.00159	0.00199	CcSEcCtD
Vigabatrin—Fatigue—Capecitabine—esophageal cancer	0.00159	0.00199	CcSEcCtD
Vigabatrin—Vision blurred—Methotrexate—esophageal cancer	0.00159	0.00199	CcSEcCtD
Vigabatrin—Rash—Cisplatin—esophageal cancer	0.00158	0.00198	CcSEcCtD
Vigabatrin—Pain—Capecitabine—esophageal cancer	0.00158	0.00198	CcSEcCtD
Vigabatrin—Constipation—Capecitabine—esophageal cancer	0.00158	0.00198	CcSEcCtD
Vigabatrin—Dermatitis—Cisplatin—esophageal cancer	0.00158	0.00198	CcSEcCtD
Vigabatrin—Ill-defined disorder—Methotrexate—esophageal cancer	0.00156	0.00196	CcSEcCtD
Vigabatrin—Anaemia—Methotrexate—esophageal cancer	0.00156	0.00195	CcSEcCtD
Vigabatrin—Feeling abnormal—Capecitabine—esophageal cancer	0.00152	0.00191	CcSEcCtD
Vigabatrin—Malaise—Methotrexate—esophageal cancer	0.00152	0.0019	CcSEcCtD
Vigabatrin—Vertigo—Methotrexate—esophageal cancer	0.00152	0.00189	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00151	0.00189	CcSEcCtD
Vigabatrin—Nausea—Cisplatin—esophageal cancer	0.00149	0.00186	CcSEcCtD
Vigabatrin—Cough—Methotrexate—esophageal cancer	0.00147	0.00184	CcSEcCtD
Vigabatrin—Urticaria—Capecitabine—esophageal cancer	0.00147	0.00184	CcSEcCtD
Vigabatrin—Abdominal pain—Capecitabine—esophageal cancer	0.00146	0.00183	CcSEcCtD
Vigabatrin—Body temperature increased—Capecitabine—esophageal cancer	0.00146	0.00183	CcSEcCtD
Vigabatrin—Convulsion—Methotrexate—esophageal cancer	0.00146	0.00183	CcSEcCtD
Vigabatrin—Chest pain—Methotrexate—esophageal cancer	0.00144	0.0018	CcSEcCtD
Vigabatrin—Myalgia—Methotrexate—esophageal cancer	0.00144	0.0018	CcSEcCtD
Vigabatrin—Arthralgia—Methotrexate—esophageal cancer	0.00144	0.0018	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00143	0.00178	CcSEcCtD
Vigabatrin—Discomfort—Methotrexate—esophageal cancer	0.00142	0.00177	CcSEcCtD
Vigabatrin—Confusional state—Methotrexate—esophageal cancer	0.00139	0.00174	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00138	0.0103	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—GNG7—esophageal cancer	0.00137	0.0102	CbGpPWpGaD
Vigabatrin—Infection—Methotrexate—esophageal cancer	0.00137	0.00171	CcSEcCtD
Vigabatrin—Hypersensitivity—Capecitabine—esophageal cancer	0.00136	0.0017	CcSEcCtD
Vigabatrin—Nervous system disorder—Methotrexate—esophageal cancer	0.00135	0.00169	CcSEcCtD
Vigabatrin—Skin disorder—Methotrexate—esophageal cancer	0.00134	0.00167	CcSEcCtD
Vigabatrin—Asthenia—Capecitabine—esophageal cancer	0.00133	0.00166	CcSEcCtD
Vigabatrin—Pruritus—Capecitabine—esophageal cancer	0.00131	0.00164	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00128	0.00951	CbGpPWpGaD
Vigabatrin—Diarrhoea—Capecitabine—esophageal cancer	0.00127	0.00158	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00125	0.00933	CbGpPWpGaD
Vigabatrin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00125	0.00157	CcSEcCtD
Vigabatrin—Insomnia—Methotrexate—esophageal cancer	0.00125	0.00156	CcSEcCtD
Vigabatrin—Paraesthesia—Methotrexate—esophageal cancer	0.00124	0.00155	CcSEcCtD
Vigabatrin—Somnolence—Methotrexate—esophageal cancer	0.00122	0.00153	CcSEcCtD
Vigabatrin—Dizziness—Capecitabine—esophageal cancer	0.00122	0.00153	CcSEcCtD
Vigabatrin—Dyspepsia—Methotrexate—esophageal cancer	0.00121	0.00152	CcSEcCtD
Vigabatrin—GABBR1—GPCR ligand binding—CXCL2—esophageal cancer	0.00121	0.00898	CbGpPWpGaD
Vigabatrin—Decreased appetite—Methotrexate—esophageal cancer	0.0012	0.0015	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00119	0.00149	CcSEcCtD
Vigabatrin—Fatigue—Methotrexate—esophageal cancer	0.00119	0.00148	CcSEcCtD
Vigabatrin—Pain—Methotrexate—esophageal cancer	0.00118	0.00147	CcSEcCtD
Vigabatrin—Vomiting—Capecitabine—esophageal cancer	0.00118	0.00147	CcSEcCtD
Vigabatrin—Rash—Capecitabine—esophageal cancer	0.00117	0.00146	CcSEcCtD
Vigabatrin—Dermatitis—Capecitabine—esophageal cancer	0.00116	0.00146	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00116	0.00863	CbGpPWpGaD
Vigabatrin—Headache—Capecitabine—esophageal cancer	0.00116	0.00145	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—GDI2—esophageal cancer	0.00115	0.00856	CbGpPWpGaD
Vigabatrin—Feeling abnormal—Methotrexate—esophageal cancer	0.00113	0.00142	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00113	0.00141	CcSEcCtD
Vigabatrin—GABBR1—GPCR ligand binding—ANXA1—esophageal cancer	0.00112	0.00835	CbGpPWpGaD
Vigabatrin—Nausea—Capecitabine—esophageal cancer	0.0011	0.00137	CcSEcCtD
Vigabatrin—Urticaria—Methotrexate—esophageal cancer	0.00109	0.00137	CcSEcCtD
Vigabatrin—GABBR1—GPCR ligand binding—SST—esophageal cancer	0.00109	0.00812	CbGpPWpGaD
Vigabatrin—Body temperature increased—Methotrexate—esophageal cancer	0.00109	0.00136	CcSEcCtD
Vigabatrin—Abdominal pain—Methotrexate—esophageal cancer	0.00109	0.00136	CcSEcCtD
Vigabatrin—GABBR1—GPCR ligand binding—GHRL—esophageal cancer	0.00106	0.00792	CbGpPWpGaD
Vigabatrin—Hypersensitivity—Methotrexate—esophageal cancer	0.00101	0.00127	CcSEcCtD
Vigabatrin—Asthenia—Methotrexate—esophageal cancer	0.000988	0.00124	CcSEcCtD
Vigabatrin—Pruritus—Methotrexate—esophageal cancer	0.000974	0.00122	CcSEcCtD
Vigabatrin—Diarrhoea—Methotrexate—esophageal cancer	0.000942	0.00118	CcSEcCtD
Vigabatrin—Dizziness—Methotrexate—esophageal cancer	0.00091	0.00114	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—AKAP13—esophageal cancer	0.00089	0.00662	CbGpPWpGaD
Vigabatrin—Vomiting—Methotrexate—esophageal cancer	0.000875	0.00109	CcSEcCtD
Vigabatrin—Rash—Methotrexate—esophageal cancer	0.000868	0.00109	CcSEcCtD
Vigabatrin—Dermatitis—Methotrexate—esophageal cancer	0.000867	0.00108	CcSEcCtD
Vigabatrin—Headache—Methotrexate—esophageal cancer	0.000862	0.00108	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—KMT2D—esophageal cancer	0.000831	0.00619	CbGpPWpGaD
Vigabatrin—Nausea—Methotrexate—esophageal cancer	0.000818	0.00102	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000814	0.00606	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—AKAP13—esophageal cancer	0.000808	0.00602	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—GNG7—esophageal cancer	0.000774	0.00576	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000741	0.00551	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PDE4D—esophageal cancer	0.000739	0.0055	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000707	0.00526	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—GNG7—esophageal cancer	0.000703	0.00523	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000682	0.00508	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000678	0.00505	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—WWOX—esophageal cancer	0.000678	0.00504	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—FKBP1A—esophageal cancer	0.000645	0.0048	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000634	0.00472	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—WIF1—esophageal cancer	0.00063	0.00469	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CXCL2—esophageal cancer	0.00062	0.00461	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—SST—esophageal cancer	0.000617	0.00459	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—GHRL—esophageal cancer	0.000601	0.00447	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000582	0.00433	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—ANXA1—esophageal cancer	0.000576	0.00429	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—SST—esophageal cancer	0.00056	0.00417	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—GHRL—esophageal cancer	0.000546	0.00406	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PFN1—esophageal cancer	0.000544	0.00405	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ELMO1—esophageal cancer	0.000489	0.00364	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—AKAP13—esophageal cancer	0.000478	0.00355	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000453	0.00337	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000441	0.00328	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PDE4D—esophageal cancer	0.000437	0.00325	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GNG7—esophageal cancer	0.000415	0.00309	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—XIAP—esophageal cancer	0.000389	0.0029	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CTNNA1—esophageal cancer	0.000368	0.00274	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CXCL2—esophageal cancer	0.000366	0.00272	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PSME2—esophageal cancer	0.000342	0.00254	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PSME1—esophageal cancer	0.000342	0.00254	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ANXA1—esophageal cancer	0.00034	0.00253	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SST—esophageal cancer	0.000331	0.00246	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GHRL—esophageal cancer	0.000323	0.0024	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—NOTCH3—esophageal cancer	0.000323	0.0024	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—FBXW7—esophageal cancer	0.000317	0.00236	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—NOTCH2—esophageal cancer	0.000289	0.00215	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TGFBR2—esophageal cancer	0.000257	0.00191	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SMAD4—esophageal cancer	0.000243	0.00181	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HIF1A—esophageal cancer	0.000199	0.00148	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—KDR—esophageal cancer	0.00019	0.00141	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—NOTCH1—esophageal cancer	0.000179	0.00133	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CREBBP—esophageal cancer	0.000162	0.00121	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—EGFR—esophageal cancer	0.00016	0.00119	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000152	0.00113	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—NOS3—esophageal cancer	0.000145	0.00108	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000138	0.00103	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ERBB2—esophageal cancer	0.000136	0.00101	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CCND1—esophageal cancer	0.00012	0.000894	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CDKN1A—esophageal cancer	0.000116	0.000865	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—EP300—esophageal cancer	0.000111	0.000823	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MYC—esophageal cancer	9.64e-05	0.000717	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—EGFR—esophageal cancer	9.43e-05	0.000701	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CA—esophageal cancer	8.18e-05	0.000609	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TP53—esophageal cancer	7.91e-05	0.000589	CbGpPWpGaD
